Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION OLE: Long-term Safety of Brazikumab in Ulcerative Colitis
jRCT2011210047Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of brazikumab in autoimmune colitis (2 arms), sponsored by AstraZeneca. Primary endpoints: Adverse events incidence, Clinically significant laboratory changes and 3 more. Started Aug 2022; status: completed.
02
Drugs
brazikumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2011210047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210047.